Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

DPYD Antikörper (AA 265-370) (Alexa Fluor 594)

DPYD Reaktivität: Human WB, IF (p), IF (cc) Wirt: Kaninchen Polyclonal Alexa Fluor 594
Produktnummer ABIN2812517
  • Target Alle DPYD Antikörper anzeigen
    DPYD (Dihydropyrimidine Dehydrogenase (DPYD))
    Bindungsspezifität
    • 14
    • 5
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 265-370
    Reaktivität
    • 41
    • 14
    • 12
    • 1
    • 1
    • 1
    Human
    Wirt
    • 41
    • 2
    Kaninchen
    Klonalität
    • 40
    • 3
    Polyklonal
    Konjugat
    • 19
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser DPYD Antikörper ist konjugiert mit Alexa Fluor 594
    Applikation
    • 31
    • 12
    • 12
    • 12
    • 8
    • 5
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))
    Homologie
    Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit
    Aufreinigung
    Purified by Protein A.
    Immunogen
    KLH conjugated synthetic peptide derived from human DPYD
    Isotyp
    IgG
    Top Product
    Discover our top product DPYD Primärantikörper
  • Applikationshinweise
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 μg/μL
    Buffer
    Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
    Haltbarkeit
    12 months
  • Target
    DPYD (Dihydropyrimidine Dehydrogenase (DPYD))
    Andere Bezeichnung
    DPYD (DPYD Produkte)
    Synonyme
    DPYD antikoerper, dpyd antikoerper, zgc:77205 antikoerper, AI315208 antikoerper, DPD antikoerper, E330028L06Rik antikoerper, DHP antikoerper, DHPDHASE antikoerper, dhp antikoerper, dhpdhase antikoerper, dpd antikoerper, 14.t00017 antikoerper, DDBDRAFT_0189681 antikoerper, DDBDRAFT_0231100 antikoerper, DDB_0189681 antikoerper, DDB_0231100 antikoerper, dpyda antikoerper, zgc:153505 antikoerper, dihydropyrimidine dehydrogenase antikoerper, dihydropyrimidine dehydrogenase b antikoerper, dihydropyrimidine dehydrogenase L homeolog antikoerper, dihydropyrimidine dehydrogenase [NADP(+)] antikoerper, dihydropyrimidine dehydrogenase a, tandem duplicate 1 antikoerper, DPYD antikoerper, Dpyd antikoerper, dpydb antikoerper, dpyd.L antikoerper, EHI_012980 antikoerper, LOC5573038 antikoerper, EDI_044620 antikoerper, pyd1 antikoerper, dpyda.1 antikoerper
    Hintergrund

    Synonyms: DHP, DHPDHase, Dihydropyrimidine dehydrogenase [NADP+], Dihydropyrimidine dehydrogenase, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, DPD, DPYD, DPYD_HUMAN, MGC132008, MGC70799, OTTHUMP00000058954.

    Background: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) , also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

    Gen-ID
    1806
    Pathways
    Ribonucleoside Biosynthetic Process
Sie sind hier:
Kundenservice